TLX Should I Buy
-
$
0.000
0.000(0.000%)
At close0.000(0.000%)Aft-market
ET
Loading...
Telix Pharmaceuticals Ltd (TLX) is a good buy for a beginner investor with a long-term focus and $50,000-$100,000 available for investment. The company demonstrates strong revenue growth, positive analyst sentiment, and promising catalysts in the cancer diagnostics market. Despite a slight pre-market dip, the technical indicators and recent developments support a favorable long-term outlook.
The MACD is positive and expanding, indicating bullish momentum. RSI is neutral at 62.615, not signaling overbought or oversold conditions. The stock is trading near its pivot point of 6.994, with resistance levels at 7.613 and 7.995, suggesting potential for upward movement.
Revenue growth of 56% in FY 2025, with a projected increase to $950-$970 million in FY
Expansion of the R&D pipeline for various cancers.
Partnership with University Hospital Essen for the PROMISE-PET registry study, enhancing its position in prostate cancer diagnostics.
Analyst upgrades and increased price targets, reflecting confidence in the company's growth potential.
Concerns around regulatory approvals and flat earnings through fiscal 2027, as noted by RBC Capital.
Pre-market price dip of -0.93%, though not significant in the long-term context.
Telix Pharmaceuticals reported $804 million in revenue for FY 2025, a 56% year-over-year increase. The company projects FY 2026 revenue between $950 million and $970 million, reflecting strong growth. Increased R&D investments indicate a focus on innovation and long-term expansion.
Analysts are bullish on TLX. Citi raised its price target to $22.50 and highlighted an upcoming FDA application for its brain imaging agent, Pixclara. RBC Capital upgraded the stock to Outperform, citing a compelling risk/reward profile and valuation. Analysts view the company as having significant growth opportunities in cancer diagnostics and therapeutics.
